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Abstract
Introduction: Thyroid dysfunction has been recognised as playing a role in the coagulation cascade, but the clinical implications of this 
phenomenon are unclear. The aim of our study was to assess the predictive power of TSH measurement on the presence or absence of 
venous thromboembolism (VTE). 
Material and methods: From January 2009 to August 2012, all consecutive patients hospitalised for suspected VTE were included in the 
study. VTE was confirmed either by pulmonary angiography or compressive ultrasound. We investigated the predictive power of TSH 
concentration on the risk of VTE in univariate and multivariate analysis including the existing risk factors (age, D-dimer).
Results: A total of 232 patients were eligible for final analysis, with a median age of 70 years (IQR 58–80) and male-to-female ratio of 
124:108. VTE was confirmed in 124 patients (53.4%). TSH concentration was significantly higher in cases with VTE (median 2.17 vs. 1.76 
mIU/L, p = 0.0104), but free T4 concentrations were not found to be significantly different. Receiver operating curve analysis identified 
the cut-off of TSH > 2.686 mIU/L as a predictor of VTE with the prevalence of VTE 47.1 vs. 66.7% below and above this cut-off, p = 0.011. 
Multivariate logistic regression identified five independent predictors of VTE: male gender (odds ratio, OR = 2.22), D-dimer > 0.5 mg/L 
OR = 16.42), CRP > 5 g/L (OR = 9.178), TSH > 2.686 mIU/L (OR = 2.269), and age (OR = 0.9767/year).
Conclusions: Among patients with suspected venous thromboembolism TSH concentration was found to be an independent predictor 
of VTE in addition to gender, D-dimer, C-reactive protein (CRP), and age. (Endokrynol Pol 2015; 66 (6): 474–479)
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Streszczenie
Wstęp: Stwierdzono, że dysfunkcja tarczycy odgrywa pewną rolę w kaskadzie krzepnięcia, lecz kliniczne następstwa tego zjawiska nie 
są do końca znane. Celem niniejszego badania była ocena na ile pomiar stężenia TSH pomoże przewidzieć obecność lub brak żylnych 
powikłań zatorowo-zakrzepowych.
Materiał i metody: Badaniem objęto wszystkich pacjentów hospitalizowanych z powodu podejrzenia żylnych powikłań zatorowo-za-
krzepowych w okresie od stycznia 2009 do sierpnia 2012 roku Powikłania te potwierdzono za pomocą angiografii płuc lub USG kom-
presyjnego. Autorzy przebadali w analizie jednoczynnikowej oraz wieloczynnikowej, z uwzględnieniem istniejących czynników ryzyka 
(wiek, D-dimery), na ile pomiar stężenia TSH pomoże przewidzieć ryzyko wystąpienia powikłań zatorowo-zakrzepowych.
Wyniki: Dwustu trzydziestu dwóch pacjentów spełniało kryteria do analizy ostatecznej; średnia wieku wynosiła 70 lat (IQR 58–80), 
stosunek mężczyzn do kobiet 124/108. Powikłania zatorowo-zakrzepowe potwierdzono u 124 pacjentów (53, 4%). Stężenie TSH było 
znacznie wyższe u pacjentów, u których wykryto żylne powikłania zatorowo-zakrzepowe (średnia 2,17 vs. 1,76 mIU/l; p = 0,0104), stęże-
nie wolnej T4 nie wykazało znaczących różnic. Analiza krzywej ROC wykazała wartość graniczną TSH na poziomie > 2,686 mIU/l jako 
czynnik prognostyczny żylnych powikłań zatorowo-zakrzepowych z przewagą ich występowania u 47,1 vs. 66,7% pacjentów ze stęże-
niem TSH poniżej i powyżej wartości granicznej, p = 0,011. Wieloczynnikowa regresja logistyczna określiła pięć niezależnych czynników 
prognozujących obecność żylnych powikłań zatorowo-zakrzepowych: płeć męska (iloraz szans (OR), OR = 2,22); D-dimery > 0,5 mg/l 
(OR = 16,42); CRP > 5 g/l (OR = 9,178); TSH > 2,686 mIU/l (OR = 2,269) oraz wiek (OR = 0,9767/rok).
Wnioski: Wśród pacjentów z podejrzeniem żylnych powikłań zatorowo-zakrzepowych, stężenie TSH okazało się niezależnych czynnikiem 
prognostycznym obecności tych powikłań, oprócz płci, D-dimerów, białka C-reaktywnego (CRP) oraz wieku. 
(Endokrynol Pol 2015; 66 (6): 474–479)
Słowa kluczowe: żylne powikłania zatorowo-zakrzepowe; tyreotropina; wolna tyroksyna 
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Material and methods
All consecutive patients hospitalised with clinical 
suspicion of VTE in a single centre between January 
2009 and August 2012 were prospectively considered 
for the study. The inclusion criteria were as follows: 
hospitalisation for suspected VTE in cases with symp-
toms and signs of deep venous thrombosis (calf pain 
or tenderness, swelling, warmth, redness or discolora-
tion, dilatation of superficial veins) and/or pulmonary 
embolism (dyspnoea, tachypnoea, chest pain, cough, 
haemoptysis, cyanosis, collapse, or circulatory insta-
bility). The decision regarding suspicion of VTE was 
made by the admitting physician. Additionally, each 
patient had at least one confirmatory test. VTE was 
confirmed or excluded by a test selected by the clinical 
context. Pulmonary CT angiography was carried out 
in all cases with suspected pulmonary embolism. In 
positive cases, a lower extremity venous ultrasound 
(LEVU) was performed. Patients with suspected deep 
venous thrombosis had a LEVU and were not routinely 
screened for concomitant pulmonary embolism. LEVU 
was performed in a supine position for the femoral and 
popliteal veins and in the sitting position for the deep 
calf veins. Deep venous thrombosis (DVT) is defined as 
a failure to fully collapse the lumen of a deep vein with 
compression. In all cases the following deep veins were 
examined: iliac vein, superficial femoral veins, popliteal 
veins, and the upper third of the deep calf veins.
Patients with no confirmatory VTE test or cases 
hospitalised for diagnoses other than VTE and eventu-
ally developing VTE during hospitalisation were not 
included. We also excluded patients with a history of 
known thyroid disease and cases without available 
complete laboratory results. 
All laboratory parameters were tested on admission 
or during the first 24 hours of hospitalisation. D-dimer, 
CRP, full blood count, serum thyrotropin (TSH), and 
free thyroxine (fT4) were assessed by standard auto-
mated laboratory analysers using commercially avail-
able kits, with normal TSH defined between 0.5 and 
5.0 mIU/L and free thyroxine (fT4) between 11.5 and 
22.7 pmol/L. Since the aim of our study was focused 
only on the screening of TSH and fT4, in these cases 
thyroid antibodies could not be evaluated because 
such examinations are not reimbursed by the public 
healthcare companies. 
Statistical analysis
Results of parameters with normal (Gaussian) distribution 
confirmed by d´Agostino-Pearson test are given as a mean 
and standard deviation but most commonly the median 
and interquartile range are provided. All nonparametric 
parameters were compared by Mann-Whitney rank 
Introduction
Venous thromboembolism (VTE) represents an impor-
tant cause of morbidity and mortality in developed 
countries. In recent decades several risk factors for VTE, 
both genetic and acquired, have been described [1, 2]. 
The relationship between thyroid hormones and the 
coagulation–fibrinolytic system was reported for the 
first time a century ago. In 1913, Kaliebe reported an 
episode of cerebral vein thrombosis in a patient with 
thyrotoxicosis [3].
The pathogenesis of coagulopathies associated with 
thyroid diseases may include direct and indirect effects 
of excess or deficiency of thyroid hormones on platelet 
maturation and function, as well as on the synthesis 
and action of coagulation factors and on altered blood 
viscosity [4]. Thyroid autoimmunity may also modify 
the processes of primary and secondary haemostasis 
[3]. Overall, the interference of thyroid hormones with 
the homeostasis of the coagulation-fibrinolytic system 
seems to be complex and its pathogenetic mechanism 
might be individually determined in a particular patient 
depending on the aetiology of thyroid dysfunction as 
well as on other factors influencing the final risk of VTE.
It is generally assumed that serum free thyroxine 
(fT4) levels are related to altered coagulation param-
eters, especially FVIII, fibrinogen, FIX, and von Wille-
brand factor (VWF). It remains unknown whether this 
effect on coagulation is partially mediated by TSH. 
Recently, more evidence has been provided showing 
that TSH itself can have a direct effect in peripheral 
tissues such as bone, adipose tissue, and muscle, medi-
ated via the TSH receptor [5, 6]. Therefore, the question 
of whether TSH also affects the coagulation system 
remains to be answered [7].
Changes in coagulation–fibrinolytic disorders oc-
cur in patients with thyroid diseases and may range 
from subclinical laboratory abnormalities to clinically 
significant disturbances of coagulation and, more rarely, 
life-threatening haemorrhages or thrombotic events [4] 
According to recent literature, patients with hypothy-
roidism seem to have an increased risk of bleeding [8], 
and patients with hyperthyroidism might be at risk of 
thrombotic events. However, this finding has not been 
replicated across different patient populations [9].
Thus, there are data supportive of the hypothesis 
that thyroid function-induced disturbances have an 
impact on the coagulation-fibrinolytic system, but it 
is unclear whether the assessment of TSH or thyroid 
function in clinical practice might represent a useful 
tool to estimate the risk of VTE in a particular patient. 
In the present study, we prospectively assessed TSH 
and free T4 concentration in patients with clinical 
suspicion of VTE. 
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sum test. The risk of VTE in various categorical groups 
was compared using the chi square test. Subsequently, 
the receiver operating curve analysis was carried out to 
identify the TSH cut-off point with the best predictive 
power for VTE. Multivariate logistic regression analysis 
was performed with VTE as a dependent variable. For 
independent variables we selected parameters with sig-
nificant differences between the VTE and non-VTE groups 
(gender, D-dimer, C reactive protein, TSH levels above 
the identified cut-off). Odds ratios with 95% confidence 
intervals were calculated for each parameter. Finally, we 
calculated the Spearman correlation coefficient between 
TSH and INR and the mean platelet volume. We used the 
statistical software package MedCalc v. 14, by MedCalc 
Software, Ostend, Belgium. 
Results
A total of 232 patients met the inclusion criteria and 
were available for the final analysis. VTE was confirmed 
in 124 patients (53.4%) and excluded in 108 (46.6%). 
A summary of statistics comparing both groups is dis-
played in Table I.
Univariate analysis showed that cases with VTE 
were more often male and had significantly lower age, 
higher D-dimer and C reactive protein, and higher TSH 
concentration (Fig. 1, Table I) However, free T4 concen-
tration was not different (fT4 14.84 vs. 15.03 pmol/L, 
p = 0.0725), and the prevalence of VTE did not differ 
between the first and the fourth free T4 quartiles (44.4 
vs. 51.16%, p = 0.1276).
The ROC curve analysis of TSH as a predictor of VTE 
found that TSH > 2.686 mIU/L had a sensitivity of 42.1% 
and specificity of 75.5%, AUROC = 0.602 (0.525–0.679). 
TSH concentration below and above this cut-off was 
significantly associated with the risk of VTE 47.1 vs. 
66.7%, p = 0.011 (Fig. 2). 
Multivariate logistic regression using parameters sig-
nificantly different between the VTE and non-VTE group 
included age, gender, CRP, D-dimer, and TSH. All five 
parameters were confirmed as independent predictors of 
VTE: age (odds ratio, OR = 0.9767/year, 95% confidence 
interval (CI) 0.9576–0.9961), D-dimer > 0.5 mg/L FEU 
(OR = 16.64, 95% CI 2.04–135.46), CRP > 5 g/L (OR = 9.29, 
95%CI 2.5–34.4), TSH > 2.686 mIU/L (OR = 2.307, 95% CI 
1.17–4.54), and male gender (OR 2.01, 95% CI 1.06–3.81), 
with 70.05% of cases correctly classified (Table II).
Considering the underlying mechanism of VTE 
in cases with increased TSH, we confirmed that cases 
with TSH above the normal range had significantly 
Table I. Summary statistics of the study group
Tabela I. Miara rozkładu cech badanej grup
Summary statistics table  
of the study qroup (n = 232)
Non VTE group (n = 108) VTE group (n = 124) p
Median IQR Median IQR
Age 74 5 60.500 to 83.000 68 53.000 to 78.000 0.0051
Male gender 33% 0.000 to 1.000 50.40% 0.000 to 1.000 0.0146
Body mass index [kg/m2] 26.67 27.18 to 32.03 28.68 25.41 to 32.81 0.1369
D dimer [mg/L FEU] 1.5 0.740 to 4.405 6.57 2.545 to 12.590 <0.0001
CRP  [g/L] 21.35 5.30 to 78.59 31 16.2 to 84.53 0.0072
fT4 [pomo/L] 15.03 12.940 to 17.230 14 84 13.745 to 16.855 0.0725
TSH [mlU/L] 1.763 0.769 to 2.686 2.17 1.293 to 3.620 0.0104
Neutrophil count 6 61 4.74 to 9.07 6.82 5.08 to 9.180 0.777
Lymphocyte count 1.375 1.00 to 1.80 1.53 1.058 to 2.030 0.2621
Neutrophil lymphocyte ratio 4.715 3.171 to 7.156 4.133 3.031 to 7.383 0.5171
Platelet  count x 10(9)/L 246 194 to 293.5 220 177 to 280 0 154 1
Mean platelet volume 10.6 10.1o to 11.40 10.5 9.90 to 1.125 0.298
International normalized ratio (INR) 1.07 1.008 to 1.162 1.09 1.01 to 1.19 0.4873
% %
TSH above normal range [> 4.87 mlU/L] 11.2 13.2 0.8275
TSH below normal range [< 0.5 mlU/L] 14 3 6.14 0 0803
TSH >2.686 [mlU/L] 24.5 42.1 0.0106
D dimer above normal range 87 99.2 < 0.0001
CRP >5 q/L 76.4 95.9 < 0.0001
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higher INR compared to cases with normal or low TSH, 
median 1.12 vs. 1.07, p = 0.0066 (Fig. 3). There was also 
a significant positive correlation between INR and mean 
platelet volume (rho = 0.185, p = 0.0070). However, we 
found no significant correlation between TSH and INR 
or TSH and mean platelet volume, rho = 0.113, p = 0.11 
and rho = 0.008, p = 0.90.
Discussion
In the present study, we prospectively evaluated 
the clinical value of TSH measurement in determin-
ing the risk of VTE in patients hospitalised with 
clinical suspicion of VTE. We found that patients with 
TSH > 2.69 mIU/L regardless of the thyroid dysfunction 
had an elevated risk of VTE compared with patients 
with TSH below this cut-off. In addition, TSH above 
this cut-off was an independent predictor of VTE as 
well as age, D-dimer, CRP, and male gender. Cases with 
TSH above the normal range had slightly higher INR, 
but we found no correlation between TSH and INR or 
mean platelet volume.
Clinically overt hypothyroidism and hyperthyroid-
ism can modify the haemostatic system in opposite 
directions [10]. Disorders of the coagulation-fibrinolytic 
system usually range from mild to moderate and rarely 
cause severe laboratory abnormalities. Some reports 
showed that patients with overt hyperthyroidism 
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Figure 1. TSH concentration in nonVTE and VTE groups in 
232 consecutive patients
Rycina 1. Stężenie TSH w grupie 232 pacjentów nonVTE 
i z VTE
Figure 2. Prevalence of VTE in cases below or above the identified 
TSH cutoff 2.686 mIU/L
Rycina 2. Przewaga VTE w przypadkach niższej lub wyższej 
stwierdzonej wartości granicznej TSH 2,686 mIU/l
Table II. Multivariate logistic regression of predictive factors 
of venous thromboembolism in 232 consecutive cases
Tabela II. Wieloczynnikowa regresja logistyczna czynników 
predykcyjnych dla żylnej choroby zakrzepowo-zatorowej 
w grupie 232 pacjentów
Odds ratio 95% confidence  
interval
p
D dimer  
above normal
16.6463 2.0456 to 135.4606 0.0086
CRP  
above normal
9.2909 2.5048 to 34.4626 0.0009
TSH  
> 2.686 mlU/L
2.3079 1.1722 to 4.5438 0.0155
Male 2.0108 1.0620 to 3.8073 0.032
0.9767 0.9576 to 0.9961 0.0189
P < 0.0001, 70.05% of cases correctly classified,  
AUROC = 0.773 (0.709–0.828)
1.4
1.3
1.2
1.1
1.0
Below normal/normal TSH
TSH normal range 0.5–5.0 mlU/L
INR 1.07 (IQR 1.0–1.16) vs. 1.12 (IQR 1.0825–1.2275), p = 0.0066
IN
R
TSH above normal
Figure 3. INR values in cases with low and normal TSH vs. 
high TSH
Rycina 3. Wartości INR dla pacjentów z niskim lub prawidłowym 
stężeniem TSH vs. wysokim stężeniem TSH
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had shortened activated partial thromboplastin time, 
higher fibrinogen levels, and significant increases in 
the turnover of factor FII, FVII, and FX [11]. Similarly, 
patients with hyperthyroidism were found to have 
decreased levels of FIX, von Willebrand factor (VWF), 
antithrombin, and PAI-1, as well as decreased levels of 
t-PA, suggesting reduced plasma fibrinolytic capacity 
and predisposing them to a hypercoagulable state [12, 
13]. Furthermore, studies have demonstrated that in 
hyperthyroid patients the balance between t-PA and 
PAI-1 appears to favour PAI-1, resulting in impaired 
endothelial function. Therefore, patients with hyper-
thyroidism may often have accompanying endothelial 
dysfunction and hypercoagulable states that contribute 
to the development of venous thrombosis and increased 
risk of PE [14].
Coagulation abnormalities in patients with thyroid 
deficiency consist of a defect of primary haemostasis, 
which results in a bleeding tendency that is usually mild 
(e.g. nose or gingival bleeding, menorrhagia, easy bruis-
ing), but which can, rarely, be severe (e.g. haemorrhages 
following trauma or surgery) [15]. Coagulation tests in 
patients with hypothyroidism usually show prolonga-
tion of the APTT and a normal or slightly shortened PT, 
reflecting the abnormalities of the related coagulation 
factors [16, 17] Hypothyroidism, which is usually associ-
ated with depression of a variety of coagulation factors, 
was first observed by Egeberg and Simone, who found 
a significant decrease of factor VIII, IX, and XI levels in 
hypothyroid patients [18]. Other studies described low 
levels of plasma coagulation factors VII, X, and XII [16].
Conversely, one recent retrospective study based on 
National Hospital Discharge Survey data showed con-
tradictory results. Danescu et al. reported that among 
633,000 US patients discharged from non-Federal hospi-
tals with hyperthyroidism during the years 1979–2005, 
the risk of PE and DVT was not significantly higher 
than in all other patients with no thyroid dysfunction 
(relative risk 0.98, 95% CI 0.96–1.01). A high risk of VTE 
was shown in patients with hypothyroidism but not in 
those with hyperthyroidism. 
In a large population-based case-control study 
(MEGA-study) into the aetiology of VTE levels of fT4, 
TSH, and antiTPO and coagulation factors FII, FVII, 
FVIII, FIX, FX, and VWF, antithrombin, protein C and 
S, and fibrinogen were determined. High levels of fT4 
were associated with increased concentrations of proco-
agulant factors, and not with levels of the anticoagulant 
factors. High levels of fT4 were also associated with 
the risk of VTE, up to an OR of 2.2 (95% CI 1.0–4.6) for 
levels above 24.4 pmol/L relative to fT4 levels between 
15.5 and 18.9 pmol/L. Low TSH levels were also, but less 
evidently, associated with thrombosis, while there was 
no association with antiTPO and VTE risk [19]. 
Thus, arguments from observations published thus 
far are rather conflicting and the underlying mechanism 
is therefore speculative. More specifically, it is not clear 
whether it is related to the effect of thyroid hormones or 
this effect is a direct effect of TSH, or if TSH itself is only 
a biomarker reflecting the overall increased risk of VTE 
from other causes. The results of our study suggest that 
this effect is independent of the thyroid function since 
free T4 levels were not significantly associated with 
the risk of VTE. From our data and from the available 
evidence we might speculate that increased TSH could 
influence both the coagulation cascade and the platelet 
volume and function. Slightly elevated INR in cases 
with high TSH could be one part of the mechanism, but 
alone it does not seem to shift the coagulation balance. 
The other part of the mechanism could be the platelet 
function. Recent reports showed that in subjects with 
subclinical hypothyroidism defined by elevated TSH 
levels above the normal rage, there was an increase 
in the mean platelet volume (MPV). Thus, in cases 
with TSH above the normal range, and even among 
subjects with upper TSH tertiles, the increased risk of 
VTE could be explained by larger and more activated 
platelets [20, 21]. However, in our study we measured 
the platelet count and the mean platelet volume and we 
did not observe any significant differences. We found 
a positive correlation between INR and the mean plate-
let volume but no correlation between TSH and INR or 
MPV. This finding might be due to the methodology of 
MPV measurement, which in our case was done only 
on automated analysers. The same was true for the dif-
ferential while blood cell count, which had no predictive 
value for VTE in our study (Table I).
When comparing our results with the above-
mentioned studies one must keep in mind that our 
study was carried out on a different study population, 
namely hospitalised cases with high risk of VTE and 
with no clinical indices of thyroid dysfunction. It was 
specifically designed to assess the clinical benefit of 
determining TSH and fT4 as a putative predictive factor 
of VTE risk in this clinical context. We found that TSH, 
but not free T4, above a defined cut-off is associated 
with higher risk of VTE. However, TSH values are in 
the normal range in the vast majority of cases and our 
cut-off was in the mid-range of normal values. Thus, 
TSH appears to be a biomarker of VTE independently 
of the thyroid function and other well-known VTE 
predictors (D-dimer, age, gender, CRP). However, the 
question remains whether TSH values are influenced by 
the thyroid function or by other factors in the context of 
an acute illness and comorbidities, or both. This finding 
must therefore be confirmed by a prospective study 
designed specifically to assess the complementary role 
of TSH to the currently used risk assessment indexes 
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(Wells score, etc.), which is not provided by our study 
and is currently underway.
A similar concept of TSH as a biomarker was al-
ready described in another non-thyroid pathology: 
metabolic bone disease [22]. The level of TSH con-
centration within the normal range was found to be 
a marker of bone health and a predictor of hip fractures 
in women [23].
The surprising finding of age as a protective fac-
tor of VTE can be explained by our particular study 
population. Older patients had a higher probability of 
alternative causes of this clinical condition, namely lung 
infection and/or cardiac failure, cellulitis, or anaemia, 
and therefore their relative prevalence of VTE was 
lower compared to younger patients. The same was 
true about the elevated C reactive protein as a risk 
factor of VTE. Some studies previously reported that 
normal CRP could have a role in excluding pulmonary 
embolism [24, 25]. Elevated CRP was probably caused 
by multiple factors such as infection, which is itself a risk 
factor for VTE, but also by the deep venous thrombosis. 
Moreover, cases with normal CRP were more likely 
to have an alternative diagnosis, such as anaemia or 
congestive heart failure, which could have a similar 
clinical picture to VTE. 
Our study has several limitations. The study group 
included patients with several comorbidities, which 
could influence the clinical and the laboratory picture. 
The exact impact and quantification of present comor-
bidities on the risk of VTE itself could not be assessed. 
Furthermore, TSH values could also be influenced by 
the comorbidities and the context of an acute illness. It 
was therefore impossible to evaluate the effect of acute 
illness and comorbidities on the concentration of TSH. 
Nevertheless, TSH in our study was associated with 
VTE independently of age, the strongest predictor of 
concomitant diseases and TSH values. 
In conclusion, TSH seems to be related to an in-
creased risk of VTE independently of age, gender, CRP, 
and D-dimer and independently of thyroid function. 
Further studies are needed to provide definite answers 
on the usefulness of TSH measurement in the predic-
tion of VTE and on the mechanism underlying this 
association. 
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